Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.
about
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Mortality in patients with int ...... b or TNFi as a first biologic.
@en
type
label
Mortality in patients with int ...... b or TNFi as a first biologic.
@en
prefLabel
Mortality in patients with int ...... b or TNFi as a first biologic.
@en
P2093
P2860
P1433
P1476
Mortality in patients with int ...... b or TNFi as a first biologic.
@en
P2093
Clive Kelly
Deborah P M Symmons
Kath D Watson
Katie L Druce
Kimme L Hyrich
Kundan Iqbal
P2860
P304
P356
10.1136/RMDOPEN-2017-000473
P577
2017-07-13T00:00:00Z